STAT+: At ESMO, AstraZeneca’s cancer pursuits get a showcase

Four of the 12 presentations in the ESMO congress presidential sessions featured AstraZeneca drugs, showcasing the company's broad oncology R&D pipeline. The content included new combinations of approved drugs and a spotlight on what could be the next targeted chemotherapy to reach the market. Susan Galbraith, head of AstraZeneca's cancer R&D, said the presentations reflect the breadth of the portfolio as well as the depth and quality of the data.